Please use this identifier to cite or link to this item:
Title: Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.
Authors: Gutiérrez-Gutiérrez, Belén
Bonomo, Robert A
Carmeli, Yehuda
Paterson, David L
Almirante, Benito
Martínez-Martínez, Luis
Oliver, Antonio
Calbo, Esther
Peña, Carmen
Akova, Murat
Pitout, Johann
Origüen, Julia
Pintado, Vicente
García-Vázquez, Elisa
Gasch, Oriol
Hamprecht, Axel
Prim, Nuria
Tumbarello, Mario
Bou, German
Viale, Pierluigi
Tacconelli, Evelina
Almela, Manel
Pérez, Federico
Giamarellou, Helen
Cisneros, José Miguel
Schwaber, Mitchell J
Venditti, Mario
Lowman, Warren
Bermejo, Joaquín
Hsueh, Po-Ren
Mora-Rillo, Marta
Gracia-Ahulfinger, Irene
Pascual, Alvaro
Rodríguez-Baño, Jesús
metadata.dc.subject.mesh: Aged
Anti-Bacterial Agents
Enterobacteriaceae Infections
Middle Aged
Retrospective Studies
Survival Analysis
Treatment Outcome
Issue Date: 22-Feb-2016
Abstract: Data about the efficacy of ertapenem for the treatment of bloodstream infections (BSI) due to ESBL-producing Enterobacteriaceae (ESBL-E) are limited. We compared the clinical efficacy of ertapenem and other carbapenems in monomicrobial BSI due to ESBL-E. A multinational retrospective cohort study (INCREMENT project) was performed ( identifier: NCT01764490). Patients given monotherapy with ertapenem or other carbapenems were compared. Empirical and targeted therapies were analysed. Propensity scores were used to control for confounding; sensitivity analyses were performed in subgroups. The outcome variables were cure/improvement rate at day 14 and all-cause 30 day mortality. The empirical therapy cohort (ETC) and the targeted therapy cohort (TTC) included 195 and 509 patients, respectively. Cure/improvement rates were 90.6% with ertapenem and 75.5% with other carbapenems (P = 0.06) in the ETC and 89.8% and 82.6% (P = 0.02) in the TTC, respectively; 30 day mortality rates were 3.1% and 23.3% (P = 0.01) in the ETC and 9.3% and 17.1% (P = 0.01) in the TTC, respectively. Adjusted ORs (95% CI) for cure/improvement with empirical and targeted ertapenem were 1.87 (0.24-20.08; P = 0.58) and 1.04 (0.44-2.50; P = 0.92), respectively. For the propensity-matched cohorts it was 1.18 (0.43-3.29; P = 0.74). Regarding 30 day mortality, the adjusted HR (95% CI) for targeted ertapenem was 0.93 (0.43-2.03; P = 0.86) and for the propensity-matched cohorts it was 1.05 (0.46-2.44; P = 0.90). Sensitivity analyses were consistent except for patients with severe sepsis/septic shock, which showed a non-significant trend favouring other carbapenems. Ertapenem appears as effective as other carbapenems for empirical and targeted therapy of BSI due to ESBL-E, but further studies are needed for patients with severe sepsis/septic shock.
metadata.dc.identifier.doi: 10.1093/jac/dkv502
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.